Table 2 Characteristics of perforation and management*
Variable | Number (%) |
|---|---|
Perforation at primary tumor site | |
Yes | 21 (24) |
No | 33 (37) |
Unknown | 35 (39) |
Perforation site | |
Colorectal | 46 (52) |
Small bowel | 19 (21) |
Stomach | 3 (3) |
Unknown | 21 (24) |
Median interval from last bevacizumab to perforation in weeks (range) | 3.8 (< 1, 232) |
Management | |
Surgical | 39 (44) |
Non-surgical | 50 (56) |